Tonix Pharmaceuticals stock halted ahead of FDA approval news
NEW YORK - UnitedHealth Group (NYSE:UNH), currently trading near its 52-week low amid broader market volatility, announced Thursday that Wayne S. DeVeydt will become its new chief financial officer effective September 2, 2025, replacing John F. Rex, who will transition to a role as strategic advisor to the CEO. According to InvestingPro data, UnitedHealth maintains strong financial health with a market capitalization of $226 billion.
DeVeydt, 55, most recently served as a managing director and operating partner at Bain Capital. His healthcare industry experience includes serving as chairman and CEO of Surgery Partners, Inc. from 2018-2020 and as CFO of Anthem, Inc. (now Elevance) from 2007 to 2016. Earlier in his career, DeVeydt was a partner at PricewaterhouseCoopers LLP focusing on the healthcare sector.
Rex, 63, has been with UnitedHealth Group since 2012 and has held the CFO position since 2016. He previously served as CFO of the company’s Optum business.
UnitedHealth Group Chairman and CEO Stephen J. Hemsley cited DeVeydt’s "deep financial acumen and operating experience" in the announcement of the appointment.
In a statement included in the press release, DeVeydt said, "There is no organization besides UnitedHealth Group that presents the kinds of opportunities to make a difference in health care, from individual patient care to broad system efficiency."
UnitedHealth Group operates through two main business segments: Optum, which delivers technology-enabled healthcare services, and UnitedHealthcare, which provides health benefits and insurance coverage.
In other recent news, UnitedHealth Group’s earnings and revenue results have been a focal point for analysts. Concerns about OptumHealth were highlighted in UnitedHealth’s second-quarter 2025 earnings report, leading Baird to downgrade the stock from Neutral to Underperform. Fitch Ratings has revised UnitedHealth’s outlook to negative from stable, citing profit pressure, while maintaining its financial strength ratings. KeyBanc lowered its price target for UnitedHealth to $350 from $400, maintaining an Overweight rating and noting the need for a credible earnings per share baseline. Similarly, RBC Capital reduced its price target to $286 from $355, maintaining an Outperform rating and noting margin headwinds. Cantor Fitzgerald reiterated an Overweight rating with a price target of $440, projecting a potential turning point with revised earnings per share estimates for the coming years. These developments reflect the varied analyst perspectives on UnitedHealth’s financial performance and future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.